Board of Scientists

Dr. THAM Seng Kong


PhD. , MD (PRC)

Dr. THAM is an established member of the Malaysian Society for Stem Cell Research & Theraphy (MSCRT) and the Malaysia Association for Cell Therapy (MACT) in Malaysia. He is a veteran in the field of life sciences, with a genuine passion for the field of Cellular Therapy. Dr. THAM earned his Bachelor of Medicine from Xiamen University, Doctor of Medicine (MD) Integrated Chinese Medicine & Western Clinical Medicine (Oncology) from Guangzhou University of Chinese Medicine (GUCM) and Doctor of Medicine (MD) in Biomedical Engineering. Presently he has the privilege of treating and consulting international members of royalty, celebrities, and members of the elite. A well sought-after Educator on Best Practices, he also dedicates his time between clinical physicians and members of the public.

He is involved in ongoing extensive research on anti-aging cellular therapy since 2006. He works very closely with his Swiss and Asian counterparts in advancing the human understanding of cellular therapy and is eager to share his experiences in this field. A well sought-after Educator on Best Practices, he also dedicates his time between clinical physicians and members of the public.

He also actively participates in cancer research. One of his important scientific breakthroughs is the discovery of penetrating tyrosinase inhibitor to reduce the production of melanin for skin beauty and whitening. He also described in his recent publication on the successful construction of retroviral transfection system that could be developed as a means of gene therapy for hepatic carcinoma.

Dr. Tham as Group Chief Executive Officer and Group Chief Research Scientist will be the main personality leading and driving the ALPS Group to greater heights towards recognition as a global biotechnology company serving humanity.

Ding Kexiang, male, 56 years old, national expert, professor, post-doctorate. He is currently a professor and chief expert on research topics at the School of Public Health and Tropical Medicine of the Southern Medical University of China (see the school’s official website www.smu.edu.cn for details); at the same time, he also serves as the American Institute of Biomedical Technology in Virginia, USA ( ABTRI) Director of molecular medicine laboratory and chief professor and chief scientist. Before studying in the United States (before 1999), he served as a visiting doctoral tutor at the Basic Medical College of Bethune Medical University and a member of the echelon of doctoral tutors at the Institute of Integrated Chinese and Western Medicine, Sun Yat-sen Medical University. When studying in American universities, he was a senior visiting research scholar and visiting professor at the University of Virginia, a visiting scholar at Harvard University, and a postdoctoral research scholar at the Center for Cell and Gene Therapy, Baylor College of Medicine.

Prof.Ding won the title of “National Young and Middle-aged Scientific and Technological Experts with Outstanding Contribution” awarded by the Chinese government in 1992 and won the “Special Government Allowance Expert” awarded by the State Council of the People’s Republic of China in the same year (1992) special government subsidy issued by the State Council; moreover, they were also awarded the “First China Young Scientist Entrepreneurship Award” by the China National Youth Federation, the “Bioengineering Expert” awarded by the Chinese People’s Association, and the formerly recognized research professor of the National Science and Technology Commission of China , The research professor appraised by the Chinese Academy of Management Sciences, and the “6th Top Ten Outstanding Young People in Guangzhou (ranked at the top of the list of top ten outstanding young people according to personal achievements)” awarded by the Guangzhou Municipal Government of China. Awarded “Top Ten Rookie of Science and Technology”. Note: Both China’s Guangzhou City and Wuhan City are China’s super international cities (super-large cities), and their urban populations exceed 10 million people.

In 2006, he was specially appointed as the lifelong chief scientist by the International Nutrition and Hygiene Research Institute in Toronto, Canada, and as the lifelong honorary chairman by the Canadian International Institute of Health Sciences and Technology. In 2003, he was awarded the lifelong honorary chairman by the North American Beauty and Health Association in Vancouver, Canada. Specially appointed as a visiting professor and academic advisor by Tai E College of Traditional Chinese Medicine in Quebec, Canada; and has been the chairman of the expert committee of the Organizing Committee of the Southeast Asian Regional Medical Aesthetic Conference since 1995; Counselor, expert committee member of CIDESIC SECTION in Hong Kong, academic adviser of Taiwan Free Radical Biomedical Research Center; concurrently serves as vice chairman of China Anti-aging Science and Technology Society, expert committee member of China Health Care Association, vice chairman of China Beauty Industry Association, etc .; on Free Radical Biomedicine, editor-in-chief and deputy editor-in-chief of Chinese Journal of Gerontology, the most authoritative academic journal of Chinese geriatrics, executive editor-in-chief and deputy editor of Chinese classic medicine “Chinese Anti-aging Medicine” medical Journals of Science, Practical Geriatrics, Modern Geriatrics, Microcirculation, Chinese Cosmetics Magazine, Chinese Science and Beauty Journal, American Toiletries Magazine (Chinese version), Taiwan Free Radical Biomedical Journal, etc. Magazine’s expert editorial board and other posts.

Geriatrics and biology, molecular diagnostics of geriatrics, medical biochemistry and cell physiology; main research directions before studying in the United States: aging free radical biology and medicine, anti-aging preparations and pharmacology, animal tissue and intracellular anti-aging Active protein (including enzymes) and peptide extraction, separation and purification technology, etc .; the main research directions in the United States: recombinant genes for early diagnosis of cancer and nanoparticle targeted therapy, early intervention of cells and genes and clinical treatment; after returning to the United States Main research directions:

(1) Biological and medical research on antioxidants and free radical scavengers;

(2) Research on transdermal drug delivery system and nano emulsion delivery system;

(3) Extraction and purification of marine bioactive peptide factors and natural plant active ingredients applied research on facial beauty and skin anti-aging subjects

(4) Research on intelligent light control and temperature control skin ultraviolet protection system and slow / controlled release system;

(5) Recombinant human fat cell receptor agonist hNPY and its receptor antagonist NPYR in human fat redistribution;

(6) Research on molecular diagnostic technology and detection system of cancer early genes;

(7) Clinical application research of autologous plasma fibrin cell scaffolds and mesenchymal stem cell proliferation induction and differentiation promotion;

(8) Application research on skin anti-aging;

(9) Molecular mechanism of skin photo-aging and anti-skin aging preparations. In addition, the research on the biomedical mechanism of tumour free radicals, the early diagnosis of tumour marker genes and the research of intelligent integrated sensitive system, etc.

Prof. DING Kexiang


Dr. Zuo Xia-Lin


BSc. (PRC), MD. (PRC), PhD. in Medicine (Pharmacology) (PRC)

Prof. Zuo graduated from Southwest China Medical University with a degree of Bachelor of Science in 2007. He also graduated from South China University of Medical Pharmacy with a degree in medical in 2010. Besides, he graduated with a doctorate in Medicine from Southern Medical Pharmacology in Jun 2013.

Prof. Zuo had hosted the National Natural Science Foundation of China Youth Project and China Post-doctoral Science Foundation projects. He had also participated in the China National Natural Science Foundation of Guangdong province and China Natural Science Foundation research project of Guangzhou city which is a scientific and technological research. Prof. Zuo participated in publishing more than 10 papers of thesis; he is also the first author who has published SCI thesis for 8 papers.

Prof. Zuo has also participated in 25 patency applications of which 12 of them is related to invention patency. He had won the national doctoral research scholarship in 2012 and “Hong Kong Scholar” award in 2016.

Dr. TAN Jun Jie graduated from Universiti Putra Malaysia in 2007 majoring in Biomedical Sciences (First class) and obtained his doctoral degree from the University of Oxford (UK) in 2011 with his study in Cardiosphere-derived stem cells and regenerative medicine.

He was also a Visiting Research Fellow in King’s College London in 2014 and a postdoctoral research fellow at Massachusetts General Hospital, Harvard Medical School (US) in 2016.

He was awarded the excellent service award in 2015 by Universiti Sains Malaysia and received the recognition for molecular medicine with the ‘Young Investigator Award’ twice (in 2013 and 2015); for his work in harnessing bone marrow mesenchymal stem cells for enhancing c-kit cardiac stem cell functions.

Dr. TAN is currently serving Universiti Sains Malaysia at Advanced Medical and Dental Institute in Kepala Batas, Penang, as a senior lecturer to continue his research venture on heart tissue engineering and regeneration using human-derived induced pluripotent stem cells. He is also looking into the concept of re-utilising the native extracellular matrix scaffold in organ from cadaveric donor as the blueprint with preserved architecture for homing cellular blocks to make engineering functional organ possible.

His current work focuses on derivation of proepicardial cells, sinoatrial-like pacemaker cells and ventricular cardiomyocytes from iPSCs to their potential in therapeutic applications.

Dr. TAN Jun Jie


BSc in Biomedical Science (UPM), DPhil (Oxford), PostDoc (Harvard)

GOH Yuh Shan

Vice President/ Head, MyGenome Molecular Institute

BSc (Hons) in Biotechnology (Monash University)

Ms. YS Goh is currently the Vice President/ Head of Mygenome Molecular Institute. She graduated from Monash University Malaysia in Bachelor of Science (Hons) in Biotechnology. She was an active scientist in National Antarctic Research Centre (NARC), University of Malaya from 2004 to 2012. Her doctoral research mainly focused on genetic characterization of novel bacteria from Antarctic environments and biopolymer synthesis using palm oil and its derivatives. She has produced 7 scientific publications in journals and proceedings. Ms. YS also participated in scientific expeditions and field work studies in Rothera station (Nov 2008 – Feb 2009) and Signy Island (Dec 2005 – Jan 2006), Antarctica. Her area of expertise are cell and molecular biology, microbiology, biochemistry and organic chemistry and has received comprehensive trainings in bioinformatics and ecological field work.

Dr. TAN Shi Wei graduated from Universiti Putra Malaysia with a Bachelor of Science in Microbiology. She proceeded to delve deeper in her research studies gaining her Master’s degree & PhD in Immunobiology.

She has extensive and varied research experience, obtained several awards; 3rd International Brain Research Organisation (IBRO) School of Neuroscience, Monash University, 3rd International Neuro Malaysia Symposium, & ‘Gift Her with Life’ Education Grant (MMICARE). In her professional career life, she has numerous publications & papers on mesenchymal stem cells, bone marrow derived mesenchymal stem cells/ Cell Immunology/ Immunopharmacology / Neuroinflammation.

Dr. TAN Shi Wei


BSc in MicroBiology (UPM),
MSc in Immunobiology (UPM),
PhD in Immunobiology (UPM)

Dr. AUNG Shuh-Wen


BSc (Hons.) in Biotechnology (Malaysia),
MSc in Molecular Microbiology (UM),
PhD in Cell Biology (UM)

Dr. Aung is currently a Research Scientist at Mygenome Sdn. Bhd. She earned her PhD in Cell Biology from University of Malaya, Malaysia in 2019. Her research experiences to date have centres on the stem cell biology.

In her thesis work, she determined the micronomic and transcriptomic signatures of human mesenchymal stromal cells during in vitro passaging in order to understand the underlying molecular mechanisms causing cellular aging in stem cells. In additional, she has experience in developing and coordinating research projects in the area of stem cell biology.

A proactive, independent and fast-learning researcher with related experience in GMP facility, Dr. Aung oversee both the production and QC department of large-scale production of human MSC (Wharton’s Jelly Stem Cell) for clinical trials.

She actively assists in designing validation protocol or methodologies in order to establishing documented evidence that provides a high degree of assurance that a specific method will consistently yield results that accurately reflect the quality characteristics of the product tested.

Veronica Sainik Ronald is currently a Senior Scientist at CelestiaLab. She obtained her Ph.D at Graduate School Of Biomedical Sciences under Molecular Biology and Biochemistry Department in September 2014 under Twinning Program supported by Advanced Dental Medicine Promotion in Southeastern Asia. 

She has been Post-Doctoral Researcher at Hiroshima University, Japan with collaboration between Kyoto University, Tissue Engineering Centre UKMMC and Department of Physiology, UKMMC. She received Japanese Government (Monbukagakusho: MEXT) Scholarships. 

She also participated and established her networks/collaborations with national and international research institutes and universities. Veronica actively involved in scientific/research activities as a reviewer, invited speaker, judge/scientific committee and facilitators. 

She had experience in clinical trial project for leukaemia patient, Cancer Biobank projects, writing research proposals, conducted short Neuroscience project and assisting graduate student from national and international university. 

Her research interests on molecular biology and biochemistry, stem cell, tissue engineering, biomaterial, cancer, natural product and neuroscience. Moreover, she also versed more than 10years in the operation of current Good Manufacturing Practice (cGMP) and familiar with cell and gene therapy regulations. 

Currently, she appointed as a senior scientist cum research scientist at CelestiaLab.

Dr. Veronica Sainik Ronald


BBM (Hons.) in Biomedicine (MSU, Malaysia),
M.DSc in Dental Science (UM),
Ph.D.DSc in Dental Science (Hiroshima University, Japan),
PostDoc (Hiroshima University, Japan),
PostDoc (UKMMC)

Nur Afiqah binti Mohamad


BSc in Biotechnology (University of Queensland, Australia)

Nur Afiqah Mohamad is currently a Senior Executive (Production) cum Research Scientist at Celestialab Sdn Bhd. She graduated from University of Queensland (UQ), Australia with a degree in Biotechnology. Previously she has served as Production Executive in GMP certified stem cells-based company for 2 years.

She has experience in prioritizing, planning, scheduling, monitoring and supporting overall production operational, documentation and administration in accordance with the requirements of the Good Manufacturing Practices (GMP).

She also involved in clinical trial for Osteoarthritis. She has been exposed to national (NPRA) and international (PIC/S, US FDA, EMA and ICH) regulation in cell and gene therapy.

Dr. Sajjarattul Nurul NADIA Asyura graduated from Universiti Putra Malaysia as Bachelor of Science (Hons) in Microbiology (2012) and Doctor of Philosophy in Cancer Biology and Oncology (2017).

She has gained 5 years working experience as a graduate research assistant and teaching assistant in the Faculty of Veterinary Medicine, Universiti Putra Malaysia; in the areas of cancer biology, molecular biology and toxicology. Post-graduation, she gained 2 years and 7 months of working experience as a researcher in the Animal Science Research Institute, Malaysian Agricultural Research and Development (MARDI), Serdang. Overall, her research mainly focused on the para-clinical study of anti-tumour of herbal extracts in the leukaemia- lymphoma-bearing rats. Dr. NADIA has valuable experience in cancer research study and project management, particularly in the para-clinical trial for cancer research. She has a strong passion for cancer research and an overall enthusiast in every aspect of science including bench work, project management, educating and presenting scientific research.

During her professional career, she gained in-depth knowledge of the different mechanism in cancer development as evidenced by 6 scientific publications in the highly reputable journal and 13 scientific proceedings. She has excellent skills in managing research professionals as evidenced by four interdepartmental and one institute collaboration in leukaemia-lymphoma research. She also received an award as the best presenter in the clinical pathology at Asian Veterinary Pathology Congress, Bangalore, India. With her professional skills, Dr. NADIA is responsible for developing and managing research and laboratory protocols in the MyGenome Molecular Institute as a modern and well-managed genome institute facility in Asia.

Dr. Sajjarattul Nurul NADIA Asyura


BSc in Microbiology (UPM),
PhD in Cancer Biology & Oncology (UPM)

Dr. ZAHIAH binti Mohamed Amin


BSc in Biotechnology (UPM),
MSc in Food Biotechnology (UPM),
PhD in Cancer Biology and Oncology (UPM)

Dr. ZAHIAH graduated from Universiti Putra Malaysia as Bachelor of Science in Biotechnology, Master of Science in Food Biotechnology and Doctor of Philosophy in Cancer Biology and Oncology. She has vast experience in the areas of cancer biology, immunology, cell culture and virology. 

Dr. ZAHIAH is also knowledgeable in the cancer research study and pre-clinical cancer research trial project management. She is driven with passion for cancer research and devoted to every science aspect including bench work, educating and scientific research presenting. Throughout her years of research, she gained in-depth knowledge in cancer development and potential vaccine treatment for cancer patients in the future.

Also, through Good Practice interpersonal skills, she received an award as the “Best Oral Presenter” on the Emerging of Infectious Diseases, Sarawak, Malaysia.

Dr. Norhazwani graduated from Universiti Kebangsaan Malaysia (UKM) with a Bachelor of Engineering majoring in Biochemical Engineering, Master of Science and Doctor of Philosophy in Chemical and Process Engineering. Her research specialized in food process technology, mainly in producing halal hydrolyzed collagen and gelatin.

She is also experienced in analyzing molecular weight of protein by using SDS-Page Electrophoresis method and knowledgeable about size exclusion chromatography. Prior to this, Dr. Norhazwani had served with one of the subsidiary company of UKM Technology Sdn. Bhd. for 2 years where she gained hands on skills experiences in planning and monitoring activities in production lines for producing Halal Hydrolyzed Collagen product. Besides that, she was also involved in technology transfer as one of the engineers to commercialize halal hydrolyzed collagen product from small scale to industrial scale and part of research team for project “Novel Intensified Process for Production of Gelatine and Hydrolyzed Collagen from Agriculture Resources” which won the Silver Medal for Biolnno Awards 2010 at BioMalaysia 2010.

Dr. NORHAZWANI binti Mohd Suhimi


BE (Hons) in Biochemical Engineering,
MSc in Chemical & Process Engineering,
PhD in Chemical & Process Engineering

ZEINABsadat Masoudian


BSc in Biology (Azad University),
MSc in Biotechnology (UM)

Zeinabsadat Masoudian holds a Bachelor of Science in Biology degree from Azad University, Iran and Master of Science in Biotechnology from University of Malaya (UM) with specialization in Bioprocess Engineering to develop recovery and purification process of proteins.

Upon graduation, Zeinab served as a researcher in Stem Cell Technology at the dental faculty in UM with areas of focus including Gene expression profiling, microRNA and conditioned media of primary Mesenchymal stem cell derived from Human Wharton Jelly, Dental Pulp and Periodontal Ligament.

Prior joining MyGenome, she has served the Ministry of Finance Incorporated Biopharmaceutical Company- Inno Biologics Sdn Bhd as an executive planning position where she was responsible for transferring technology of Biosimilar monoclonal antibodies (Mabs)’s production, registration and reporting in accordance with the Good Manufacturing Practices (GMP).

She also received an award as the “Best Poster Presentation’ at the 19th Biological Sciences Graduate Congress, National University of Singapore (NUS).